

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: LaColla *et al.* Confirmation No.: 9201
Serial No.: 10/609,298 Art Unit: 1623
Filed: June 27, 2003 Examiner: T. McIntosh III
For: 2' AND 3' NUCLEOSIDE PRODRUGS Attorney Docket No: 11874-016-999
FOR TREATING FLAVIVIRIDAE (CAM: 417451-999016)
INFECTIONS IDX 1017

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Università Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II (collectively, "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of any patent granted on pending U.S. Patent Application Nos. 11/005,443 and 11/516,928 (the "reference applications"). The owners hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patents granted on the reference applications.

The owners further agree that this agreement is to run with any patent granted on the above-identified application and is to be binding upon the grantee, its successors, and assigns.


The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of any patents granted on the reference applications in the event that said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Ownership of the above-identified application and the reference applications in Idenix Pharmaceuticals, Inc., Università Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; November 11, 2008 at reel 021819 frame 0149; and the assignment attached hereto.

The undersigned hereby confirm that they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Idenix Pharmaceuticals, Inc.

Date: March 30, 2001 By: 
Name: Jean-Pierre Sammouda,
Position: Chief Executive Officer

Universita Degli Studi di Cagliari

Date: _____ By: _____
Name:
Position:

Centre National de la Recherche Scientifique

Date: _____ By: _____
Name:
Position:

L' Université Montpellier II

Date: _____ By: _____
Name:
Position:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|-----------------|--|------------------------------|---|
| Application of: | LaColla <i>et al.</i> | Confirmation No.: | 9201 |
| Serial No.: | 10/609,298 | Art Unit: | 1623 |
| Filed: | June 27, 2003 | Examiner: | T. McIntosh III |
| For: | 2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | Attorney Docket No: (CAM: | 11874-016-999 417451-999016) IDX 1017 |

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II (collectively, "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of any patent granted on pending U.S. Patent Application Nos. 11/005,443 and 11/516,928 (the "reference applications"). The owners hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patents granted on the reference applications.

The owners further agree that this agreement is to run with any patent granted on the above-identified application and is to be binding upon the grantee, its successors, and assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of any patents granted on the reference applications in the event that said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Ownership of the above-identified application and the reference applications in Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; November 11, 2008 at reel 021819 frame 0149; and the assignment attached hereto.

1.A1-2987126v2

The undersigned hereby confirm that they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.


Idenix Pharmaceuticals, Inc.

Date: _____ By: _____

Name: _____


Position: _____

Universita Degli Studi di Cagliari

Date: 23.03.2009 By: 

Name: Il RETTORE

Position: (Pasquale Mistretta)



Centre National de la Recherche Scientifique

Date: _____ By: _____

Name: _____

Position: _____

L' Université Montpellier II

Date: _____ By: _____

Name: _____

Position: _____

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|-----------------|--|------------------------------|---|
| Application of: | LaColla <i>et al.</i> | Confirmation No.: | 9201 |
| Serial No.: | 10/609,298 | Art Unit: | 1623 |
| Filed: | June 27, 2003 | Examiner: | T. McIntosh III |
| For: | 2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | Attorney Docket No: (CAM: | 11874-016-999 417451-999016) IDX 1017 |

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II (collectively, "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of any patent granted on pending U.S. Patent Application Nos. 11/005,443 and 11/516,928 (the "reference applications"). The owners hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patents granted on the reference applications.

The owners further agree that this agreement is to run with any patent granted on the above-identified application and is to be binding upon the grantee, its successors, and assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of any patents granted on the reference applications in the event that said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Ownership of the above-identified application and the reference applications in Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; November 11, 2008 at reel 021819 frame 0149; and the assignment attached hereto.

The undersigned hereby confirm that they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Idenix Pharmaceuticals, Inc.


Date: _____ By: _____
Name: _____
Position: _____

Universita Degli Studi di Cagliari

Date: _____ By: _____
Name: _____
Position: _____

Centre National de la Recherche Scientifique

Date: 30 MARS 2009 By: _____
Name: _____
Position: _____

Directeur de la Politique Industrielle

Marc J. LEDOUX

L' Université Montpellier II

Date: _____ By: _____
Name: _____
Position: _____

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|-----------------|--|------------------------------|---|
| Application of: | LaColla <i>et al.</i> | Confirmation No.: | 9201 |
| Serial No.: | 10/609,298 | Art Unit: | 1623 |
| Filed: | June 27, 2003 | Examiner: | T. McIntosh III |
| For: | 2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | Attorney Docket No: (CAM: | 11874-016-999 417451-999016) IDX 1017 |

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II (collectively, "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of any patent granted on pending U.S. Patent Application Nos. 11/005,443 and 11/516,928 (the "reference applications"). The owners hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patents granted on the reference applications.

The owners further agree that this agreement is to run with any patent granted on the above-identified application and is to be binding upon the grantee, its successors, and assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of any patents granted on the reference applications in the event that said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Ownership of the above-identified application and the reference applications in Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; November 11, 2008 at reel 021819 frame 0149; and the assignment attached hereto.

The undersigned hereby confirm that they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Idenix Pharmaceuticals, Inc.

Date: _____ By: _____
Name: _____
Position: _____

Universita Degli Studi di Cagliari


Date: _____ By: _____
Name: _____
Position: _____

Centre National de la Recherche Scientifique

Date: _____ By: _____
Name: _____
Position: _____

L' Université Montpellier II

Date: 18/03/2009 By: _____
Name: Mme Danièle HERIN
Position: Présidente



A large, handwritten signature of Danièle Herin is written diagonally across the bottom right of the document. To its right is the circular logo of the University of Montpellier II, featuring a stylized bird in the center, surrounded by the text 'UNIVERSITE MONTPELLIER II' and 'SCIENCES ET TECHNOLOGIES'.

PATENT ASSIGNMENT AGREEMENT

THIS PATENT ASSIGNMENT AGREEMENT (this "*Assignment*"), effective as of March 4, 2009 (the "*Effective Date*"), is made by and among Idenix Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware, USA ("*Idenix USA*"), Idenix SARL, a [corporation] organized under the laws of France ("*Idenix France*"), Idenix (Cayman) Limited, a company organized under the laws of the Cayman Islands ("*Idenix Cayman*"), the Università degli studi di Cagliari, a university organized under the laws of Italy ("*University of Cagliari*"), the Centre National Del La Recherche Scientifique, a [corporation] organized under the laws of France ("*CNRS*"), and L'Université Montpellier II, a [public institution] organized under the laws of France ("*UM II*"). (Idenix USA, Idenix France, Idenix Cayman, University of Cagliari, CNRS and UM II also may be referred to herein individually as a "*party*" and collectively as the "*parties*.")

RECAPITALS

A. Idenix France, on behalf of itself and Idenix USA, and CNRS and UM II are parties to that certain Restated and Amended Cooperative Joint Research Agreement dated as of May 7, 2003 (the "*French Joint Research Agreement*"), pursuant to which each of the parties thereto agreed to jointly own all "Results" (as defined therein) and patents covering such Results.

B. Idenix France, through its predecessor Novirio SARL, and the University of Cagliari are parties to that certain Co-Operative Antiviral Research Activity Agreement dated January 4, 1999, as amended (the "*Italian Joint Research Agreement*"), pursuant to which each of them have agreed to jointly own all results obtained from the activities taken thereunder and patents covering such results.

C. Idenix France, through its predecessor Novirio SARL, and Idenix Cayman, through its contributor Novirio Pharmaceuticals Limited, a corporation formerly organized under the laws of the Cayman Islands, are parties to that certain Research and Development Agreement dated as of August 24, 1998 pursuant to which Idenix Cayman owns all intellectual property rights developed pursuant to "Projects" (as defined therein), except certain of such rights owned by Idenix USA.

D. The inventors of the United States and foreign patents and patent applications listed on Attachment A assigned their individual rights, titles and interests to their respective employers before the Effective Date.

E. The parties desire that each of Idenix USA, University of Cagliari, CNRS and UM II (collectively, the "*Joint Assignees*") each jointly own an equal, undivided right, title and interest in the Jointly Owned Patents (as defined below), subject to the rights and obligations of each Joint Assignee with respect thereto set forth in the French Joint Research Agreement or the Italian Joint Research Agreement, as applicable, through partial assignments by the respective owners as of the Effective Date as necessary to accurately document and record such agreement.

AGREEMENT

NOW, THEREFORE, for good and valuable consideration (including the premises and covenants set forth in the Italian Joint Research Agreement and the French Joint Research Agreement), the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

Each of the parties (each an "*Assignor*") hereby irrevocably assigns, transfers and sets over to the Joint Assignees all or such portion of such Assignor's right, title and interest in and to the patents and patent applications listed on Attachment A (if any), together with any foreign counterparts or equivalents thereto, existing now or in the future and including, but not limited to, patents of utility, improvement or addition, utility model and appearance and industrial design patents and inventors certificates, as well as divisionals, reissues, continuations (in whole or in part), renewals and extensions of any of the foregoing and any patents that may issue from any of the foregoing or any reissues or reexaminations thereof, and including the inventions described or claimed in the foregoing (all of the foregoing, collectively, "*Jointly Owned Patents*"), for each Joint Assignee's use and enjoyment, and for the use and enjoyment of their respective successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by each Assignor if this assignment had not been made, in each case such that all of the Joint Assignees hereby jointly own an equal, undivided right, title and interest to all of the *Jointly Owned Patents*, subject to the terms and conditions of the French Joint Research Agreement and Italian Joint Research Agreement, as applicable.

Each Assignor authorizes and requests the United States Commissioner of Patents and Trademarks and any other similar government authority to record each Joint Assignee as a joint owner of the *Jointly Owned Patents* and issue any and all patents issued thereon to the Joint Assignees jointly, as assignees collectively of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of the Joint Assignees jointly and their respective successors, assigns or other legal representatives.

Assignors shall provide the Joint Assignees and their respective successors, assigns or other legal representatives, reasonable cooperation and assistance, including the execution and delivery of any and all affidavits, declarations, oaths, exhibits, assignments, powers of attorney or other documentation, as may be reasonably required in the implementation, recordation or perfection of this Assignment. Each of the parties hereby irrevocably appoints Idenix USA and its successors, assigns and other legal representatives as the true and lawful attorney-in-fact on Assignor's and Joint Assignee's behalf and in Assignor's and/or Joint Assignee's name, place and stead, to execute any further documents or instruments and do any and all further acts that may be deemed appropriate by Idenix USA and its successors, assigns and other legal representatives to effect the assignments to the Joint Assignees and their respective successors, assigns and other legal representatives, of the rights, titles and interests made hereby, and to enable such assignments to be recorded and/or perfected in the United States and all foreign countries, and to maintain, issue or extend any *Jointly Owned Patents*.

Each party is solely responsible for its costs and expenses associated with the execution and delivery of this Assignment. Each Joint Assignee shall be responsible for 25% of all of the out of pocket costs and expenses actually incurred by Idenix USA in connection with the recording or other perfection of this Assignment within the United States and all foreign

countries, including, but not limited to, any recording fees, taxes or other charges payable to any governmental authority or local attorney/agent in connection therewith.

This Assignment may be executed in one or more counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same instrument. This Assignment is governed by the laws of the State of Delaware.


<signature pages follow>

IN WITNESS WHEREOF, each of the parties have executed and delivered this Assignment to effective as of the Effective Date.

Idenix Pharmaceuticals, Inc.

By: 
Name: Jean-Pierre Sammehossi
Title: Chief Executive Officer


Idenix SARL

By: 

Name: Jean-Pierre Sonnen dessi

Title: Director

Idenix (Cayman) Limited

By: 

Name: Jean-Pierre Samandossi

Title: Director

Università degli studi di Cagliari

By: _____
Name: PA SQUALS MISTRETTA
Title: Rector

IL RETTORE
(*Pasquale Mistretta*)
benorilli



CAGLIARI, 01 APR. 2009


**Centre National Del La Recherche
Scientifique**

By: Directeur de la Politique Industrielle

Name: _____

Title: _____

Marc J. LEDOUX



L'Université Montpellier II



By: _____

Name: Mme Danièle Hézin

Title: Présidente

Attachment A

Jointly Owned Patents

(See attached.)

Attachment A for Patent Assignment Agreement

| <u>Jones Day CAM</u> | <u>Docket No.</u> | <u>Index Ref. No.</u> | <u>Type Related/ Country</u> | <u>Inventor</u> | <u>Serial No.</u> | <u>Filed</u> | <u>Title</u> |
|-------------------------------|-------------------|---------------------------|---|---|-----------------------|--------------|--|
| IDX 1017 Patent Family | | | | | | | |
| 417451-888016 | 11874-016-888 | 1017 US PROV | | Gossein, G. Sommadossi, J.-P. Moussa, A. Piema, C. Benzaria-Prad, S. Dukhan, D. LaColla, P. | 60/352,351 | 6/28/02 | 2' and 3' Nucleoside Products for Treating Hepatitis C Virus |
| 417451-999016 | 11874-016-999 | 1017 US | 11874-015-888 11874-016-888 11874-130-888 | LaColla, P. Sommadossi, J.-P. Gossein, G. Storer, R. | 10/609,298 | 6/27/03 | 2' and 3' Nucleoside Products for Treating Flaviviridae Infections |
| 417451-999047 | 11874-047-999 | 1017 US CON 1 | 11874-016-999 | Gossein, G. Storer, R. LaColla, P. Sommadossi, J.-P. | 11/005,471 | 12/6/04 | 2' and 3' Nucleoside Products for Treating Flaviviridae Infections |
| 417451-999048 | 11874-048-999 | 1017 US CON 2 | 11874-016-999 | Gossein, G. LaColla, P. Sommadossi, J.-P. | 11/005,442 | 12/6/04 | 2' and 3' Nucleoside Products for Treating Flaviviridae Infections |
| 417451-999049 | 11874-049-999 | 1017 US CON 3 | 11874-016-999 | Gossein, G. LaColla, P. Sommadossi, J.-P. | 11/005,466 | 12/6/04 | 2' and 3' Nucleoside Products for Treating Flaviviridae Infections |
| 417451-999050 | 11874-050-999 | 1017 US CON 4 | 11874-016-999 | Gossein, G. LaColla, P. Sommadossi, J.-P. | 11/005,440 | 12/6/04 | 2' and 3' Nucleoside Products for Treating Flaviviridae Infections |
| 417451-999051 | 11874-051-999 | 1017 US CON 5 | 11874-016-999 | Gossein, G. LaColla, A. Sommadossi, J.-P. | 11/005,443 | 12/6/04 | 2' and 3' Nucleoside Products for Treating Flaviviridae Infections |
| 417451-999052 | 11874-052-999 | 1017 US CON 6 | 11874-016-999 | Gossein, G. LaColla, A. Sommadossi, J.-P. | 11/005,446 | 12/6/04 | 2' and 3' Nucleoside Products for Treating Flaviviridae Infections |
| 417451-999053 | 11874-053-999 | 1017 US CON 7 | 11874-016-999 | Gossein, G. LaColla, A. Sommadossi, J.-P. | 11/005,472 | 12/6/04 | 2' and 3' Nucleoside Products for Treating Flaviviridae Infections |

1A1-293113v1
3/4/2009

| <u>Jones Day CAM</u> | <u>Docket No.</u> | <u>Identix Ref. No.</u> | <u>Type Related/ Country</u> | <u>Inventor</u> | <u>Serial No.</u> | <u>Filed</u> | <u>Title</u> |
|--------------------------|-------------------|-----------------------------|--------------------------------------|--|-----------------------|--------------|---|
| 417451-999054 | 11874-054-999 | 1017 US CON 8 | CON of 11874-016-999 | Gosselin, G. LaColla, A. Sommadossi, J.-P. | 11/005,444 | 12/6/04 | 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-001016 | 11874-016-001 | 1017 CA | Canada | Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G. | 2,490,200 | 6/27/03 | 1', 2', and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-007016 | 11874-016-007 | 1017 AU | Australia | Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G. | 2003263412 | 6/27/03 | 1', 2', and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-008016 | 11874-016-008 | 1017 NZ | New Zealand | Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G. | 537,250 | 6/27/03 | 1', 2', and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-009016 | 11874-016-009 | 1017 MX | Mexico | Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G. | PA/2004/0 12779 | 6/27/03 | 1', 2', and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-010016 | 11874-016-010 | 1017 CL | Chile | Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G. | 1336-2003 | 6/27/03 | 1', 2', and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-011016 | 11874-016-011 | 1017 PE | Peru | Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G. | 660-2003 | 6/27/03 | 1', 2', and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-012016 | 11874-016-012 | 1017 JP | Japan | Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G. | 2004- 517162 | 6/27/03 | 1', 2', and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-015016 | 11874-016-015 | 1017 NO | Norway | Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G. | 20050466 | 6/27/03 | 1', 2', and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-019016 | 11874-016-019 | 1017 RU | Russian Fed. | Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G. | 2005102096 | 6/27/03 | 1', 2', and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |

LAI-2953113v1
3/4/2009

| <u>Jones Day CAM</u> | <u>Docket No.</u> | <u>Idenix Ref. No.</u> | <u>Type Related/ Country</u> | <u>Inventor</u> | <u>Serial No.</u> | <u>Filed</u> | <u>Title</u> |
|--------------------------|-------------------|----------------------------|--------------------------------------|--|-------------------------|--------------|--|
| 417451-025016 | 11874-016-023 | 1017 HK | Hong Kong | Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G. | 05106836.0 | 8/9/05 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-025016 | 11874-016-025 | 1017 VE | Venezuela | Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G. | 1100-2003 | 6/30/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-036016 | 11874-016-036 | 1017 AR | Argentina | Storer, R. Gossein, G. Imbach, J.-L. Sommadossi, J.-P. Mousa, A. | P03010236.5 | 6/30/03 | 2' and 3' Nucleoside Products for Treating Flaviviridae Infections |
| 417451-037016 | 11874-016-037 | 1017 BR | Brazil | Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G. | P0312271.9 | 6/27/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-039016 | 11874-016-039 | 1017 PY | Paraguay | Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G. | 1596/2003 | 6/27/09 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-040016 | 11874-016-040 | 1017 UY | Uruguay | Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G. | 27.876 | 6/30/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-041016 | 11874-016-041 | 1017 BO | Bolivia | Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G. | SP-151-03 (SP223015) | 6/27/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-055016 | 11874-016-055 | 1017 SG | Singapore | Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G. | 2004/07794-7 | 6/27/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-056016 | 11874-016-056 | 1017 IN | India | Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G. | 341/RELNP 2005 | 6/27/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |

| <u>Jones Day CAM</u> | <u>Docket No.</u> | <u>Idenix Ref. No.</u> | <u>Type Related/ Country</u> | <u>Inventor</u> | <u>Serial No.</u> | <u>Filed</u> | <u>Title</u> |
|--------------------------|-------------------|----------------------------|--------------------------------------|---|-----------------------|--------------|--|
| 417451-076016 | 11874-016-076 | 1017 ID | Indonesia | Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G. | W00200500 216 | 6/27/06 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-076016 | 11874-016-078 | 1017 EG | Egypt | Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G. | 617/2003 | 6/28/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-106016 | 11874-016-106 | 1017 MA | Morocco | Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G. | 280/72 | 6/27/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-117016 | 11874-016-117 | 1017 PH | Philippines | Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G. | 1-2005- 500175 | 6/27/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-131016 | 11874-016-131 | 1017 TH | Thailand | Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G. | 083423 | 6/27/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-146016 | 11874-016-146 | 1017 CN | China | Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G. | 03820690.0 | 6/27/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-147016 | 11874-016-147 | 1017 ZA | South Africa | Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G. | 2004/10289 | 6/27/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-150016 | 11874-016-150 | 1017 PL | Poland | Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G. | P374792 | 6/27/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-154016 | 11874-016-154 | 1017 YU | Yugoslavia (former) | Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G. | P-114104 | 6/27/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |

| <u>Jones Day CAM</u> | <u>Docket No.</u> | <u>Identix Ref. No.</u> | <u>Type Related/ Country</u> | <u>Inventor</u> | <u>Serial No.</u> | <u>Filed</u> | <u>Title</u> |
|--------------------------|-------------------|-----------------------------|--------------------------------------|---|-----------------------|--------------|--|
| 417451-158016 | 11874-016-158 | 1017 IL | Israel | Sommadossi, J.-P. LaColla, P. Storer, R. Goselin, G. | 165891 | 6/27/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-178016 | 11874-016-178 | 1017 PK | Pakistan | Sommadossi, J.-P. LaColla, P. Storer, R. Goselin, G. | 5782003 | 6/27/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-185016 | 11874-016-185 | 1017 TW | Taiwan | Sommadossi, J.-P. LaColla, P. Storer, R. Goselin, G. | 92117542 | 6/27/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-187016 | 11874-016-187 | 1017 KR | South Korea | Sommadossi, J.-P. LaColla, P. Storer, R. Goselin, G. | 10-2004-7021337 | 6/27/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-189016 | 11874-016-189 | 1017 VN | Vietnam | Sommadossi, J.-P. LaColla, P. Storer, R. Goselin, G. | 12/2005-00109 | 6/27/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-214016 | 11874-016-214 | 1017 OA | OAPI | Sommadossi, J.-P. LaColla, P. Storer, R. Goselin, G. | 1200400341 | 6/27/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-227016 | 11874-016-227 | 1017 EP | EPO | Sommadossi, J.-P. LaColla, P. Storer, R. Goselin, G. | 037617493 | 6/27/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-228016 | 11874-016-228 | 1017 WO | PCT | Sommadossi, J.-P. LaColla, P. Storer, R. Goselin, G. | PCT/IB2003/003901 | 6/27/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| 417451-241016 | 11874-016-241 | 1017 MY | Malaysia | Sommadossi, J.-P. LaColla, P. Storer, R. Goselin, G. | PI20032435 | 6/27/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |

| <u>Jones Day CAM</u> | <u>Docket No.</u> | <u>Idenix Ref. No.</u> | <u>Type Related/ Country</u> | <u>Inventor</u> | <u>Serial No.</u> | <u>Filed</u> | <u>Title</u> |
|-------------------------------|-------------------|----------------------------|---|---|-----------------------|--------------|--|
| 417451-262016 | 11874-016-262 | 1017 AP | ARIPO | Sommadossi, J.-P. LaColla, P. Storer, R. Goselin, G. | APP/05/003 211 | 6/27/03 | 1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections |
| IDX 1018 Patent Family | | | | | | | |
| 417451-888055 | 11874-055-888 | 1018 US PROV | PROV | Storer, R. Goselin, G. Sommadossi, J.-P. Moussa, A. LaColla, P. | 60/592,350 | 6/28/02 | Modified 2' and 3' Nucleoside Prodrugs for Treating Hepatitis C Virus |
| 417451-999055 | 11874-055-999 | 1018 US | 11874-015-888 11874-055-888 11874-130-888 | Storer, R. Goselin, G. LaColla, P. Sommadossi, J.-P. | 10/608,907 | 6/27/03 | Modified 2' and 3' Nucleoside Prodrugs for Treating Hepatitis C Virus |
| 417451-999056 | 11874-056-999 | 1018 US CON 1 | CON of 11874-055-999 | LaColla, P. Storer, R. Goselin, G. Sommadossi, J.-P. | 11/005,445 | 12/6/04 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-999057 | 11874-057-999 | 1018 US CON 2 | CON of 11874-055-999 | LaColla, P. Storer, R. Goselin, G. Sommadossi, J.-P. | 11/005,473 | 12/6/04 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-999058 | 11874-058-999 | 1018 US CON 3 | CON of 11874-055-999 | Storer, R. Goselin, G. LaColla, P. Sommadossi, J.-P. | 11/005,468 | 12/6/04 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-999059 | 11874-059-999 | 1018 US CON 4 | CON of 11874-055-999 | LaColla, P. Storer, R. Goselin, G. Sommadossi, J.-P. | 11/005,467 | 12/6/04 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-999060 | 11874-060-999 | 1018 US CON 5 | CON of 11874-055-999 | LaColla, P. Storer, R. Goselin, G. Sommadossi, J.-P. | 11/005,470 | 12/6/04 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-999061 | 11874-061-999 | 1018 US CON 6 | CON of 11874-055-999 | Storer, R. Goselin, G. LaColla, P. Sommadossi, J.-P. | 11/005,447 | 12/6/04 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |

1A1-353113v1
3/4/2009

| <u>Jones Day CAM</u> | <u>Docket No.</u> | <u>Idenix Ref. No.</u> | <u>Type Related/ Country</u> | <u>Inventor</u> | <u>Serial No.</u> | <u>Filed</u> | <u>Title</u> |
|--------------------------|-------------------|----------------------------|--------------------------------------|---|-----------------------|--------------|--|
| 417451-999062 | 11874-062-999 | 1018 US CON 7 | CON of 11874-055-999 | Storer, R. Gossein, G. LaColla, P. Sommadossi, J.-P. | 11/005,441 | 12/6/04 | Modified 2' and 3' Nucleoside Produgs for Treating Flaviviridae Infections |
| 417451-999063 | 11874-063-999 | 1018 US CON 8 | CON of 11874-055-999 | LaColla, P. Storer, R. Gossein, G. Sommadossi, J.-P. | 11/005,469 | 12/6/04 | Modified 2' and 3' Nucleoside Produgs for Treating Flaviviridae Infections |
| 417451-999190 | 11874-190-999 | 1018 US DIV | DIV of 11874- 055-999 | LaColla, P. Storer, R. Gossein, G. Sommadossi, J.-P. | 12/131,868 | 6/2/08 | Modified 2' and 3' Nucleoside Produgs for Treating Flaviviridae Infections |
| 417451-001055 | 11874-055-001 | 1018 CA | Canada | LaColla, P. Storer, R. Gossein, G. Sommadossi, J.-P. | 2,490,191 | 6/27/03 | Modified 2' and 3' Nucleoside Produgs for Treating Flaviviridae Infections |
| 417451-007055 | 11874-055-007 | 1018 AU | Australia | Storer, R. Gossein, G. LaColla, P. Sommadossi, J.-P. | 2003247/084 | 6/27/03 | Modified 2' and 3' Nucleoside Produgs for Treating Flaviviridae Infections |
| 417451-008055 | 11874-055-008 | 1018 NZ | New Zealand | LaColla, P. Storer, R. Gossein, G. Sommadossi, J.-P. | 537663 | 6/27/03 | Modified 2' and 3' Nucleoside Produgs for Treating Flaviviridae Infections |
| 417451-009055 | 11874-055-009 | 1018 MX | Mexico | LaColla, P. Storer, R. Gossein, G. Sommadossi, J.-P. | PA/3/2004/0 12709 | 6/27/03 | Modified 2' and 3' Nucleoside Produgs for Treating Flaviviridae Infections |
| 417451-010055 | 11874-055-010 | 1018 CL | Chile | Storer, R. Gossein, G. LaColla, P. Sommadossi, J.-P. | 1337-2063 | 6/30/03 | Modified 2' and 3' Nucleoside Produgs for Treating Flaviviridae Infections |
| 417451-011055 | 11874-055-011 | 1018 PE | Peru | LaColla, P. Storer, R. Gossein, G. Sommadossi, J.-P. | 00659/2003 | 6/30/03 | Modified 2' and 3' Nucleoside Produgs for Treating Flaviviridae Infections |

| <u>Jones Day CAM</u> | <u>Docket No.</u> | <u>Idenix Ref. No.</u> | <u>Type Related/ Country</u> | <u>Inventor</u> | <u>Serial No.</u> | <u>Filed</u> | <u>Title</u> |
|--------------------------|-------------------|----------------------------|--------------------------------------|---|-----------------------|--------------|--|
| 417451-012055 | 11874-055-012 | 1018 JP | Japan | LaColla, P. Storer, R. Gossein, G. Sommadossi, J.-P. | 2004- 517158 | 6/27/03 | Modified 2' and 3' Nucleoside Produgs for Treating Flaviviridae Infections |
| 417451-012055 | 11874-055-015 | 1018 NO | Norway | Storer, R. Gossein, G. LaColla, P. Sommadossi, J.-P. | 20050465 | 6/27/03 | Modified 2' and 3' Nucleoside Produgs for Treating Flaviviridae Infections |
| 417451-012055 | 11874-055-019 | 1018 RU | Russian Fed. | Storer, R. Gossein, G. LaColla, P. Sommadossi, J.-P. | 2005102013 | 6/27/03 | Modified 2' and 3' Nucleoside Produgs for Treating Flaviviridae Infections |
| 417451-022055 | 11874-055-023 | 1018 HK | Hong Kong | LaColla, P. Storer, R. Gossein, G. Sommadossi, J.-P. | 05106974-2 | 8/12/05 | Modified 2' and 3' Nucleoside Produgs for Treating Flaviviridae Infections |
| 417451-022055 | 11874-055-025 | 1018 VE | Venezuela | LaColla, P. Storer, R. Gossein, G. Sommadossi, J.-P. | 1101-2003 | 6/30/03 | Modified 2' and 3' Nucleoside Produgs for Treating Flaviviridae Infections |
| 417451-036055 | 11874-055-036 | 1018 AR | Argentina | Storer, R. Gossein, G. LaColla, P. Sommadossi, J.-P. | P030102366 | 6/30/03 | Modified 2' and 3' Nucleoside Produgs for Treating Flaviviridae Infections |
| 417451-037055 | 11874-055-037 | 1018 BR | Brazil | Storer, R. Gossein, G. LaColla, P. Sommadossi, J.-P. | P0312286-7 | 6/27/03 | Modified 2' and 3' Nucleoside Produgs for Treating Flaviviridae Infections |
| 417451-039055 | 11874-055-039 | 1018 PY | Paraguay | Storer, R. Gossein, G. LaColla, P. Sommadossi, J.-P. | 15691/2903 | 6/27/03 | Modified 2' and 3' Nucleoside Produgs for Treating Flaviviridae Infections |
| 417451-040055 | 11874-055-040 | 1018 UY | Uruguay | Storer, R. Gossein, G. LaColla, P. Sommadossi, J.-P. | 27.875 | 6/30/03 | Modified 2' and 3' Nucleoside Produgs for Treating Flaviviridae Infections |

| <u>Jones Day CAM</u> | <u>Docket No.</u> | <u>Idenix Ref. No.</u> | <u>Type Related/ Country</u> | <u>Inventor</u> | <u>Serial No.</u> | <u>Filed</u> | <u>Title</u> |
|--------------------------|-------------------|----------------------------|--------------------------------------|---|-----------------------|--------------|---|
| 417451-041055 | 11874-055-041 | 1018 BO | Bolivia | Storer, R. Gossein, G. LaColla, P. Sommadossi, J.-P. | SP-150-03 | 6/30/03 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-055055 | 11874-055-055 | 1018 SG | Singapore | Storer, R. Gossein, G. LaColla, P. Sommadossi, J.-P. | 200407747-5 | 6/27/03 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-056055 | 11874-055-056 | 1018 IN | India | Storer, R. Gossein, G. LaColla, P. Sommadossi, J.-P. | 343/DELNP /2005 | 6/27/03 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-076055 | 11874-055-076 | 1018 ID | Indonesia | Storer, R. Gossein, G. LaColla, P. Sommadossi, J.-P. | W00200500 215 | 6/27/03 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-078055 | 11874-055-078 | 1018 EG | Egypt | Storer, R. Gossein, G. LaColla, P. Sommadossi, J.-P. | 171/2904 | 4/18/2004 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-106055 | 11874-055-106 | 1018 MA | Morocco | Storer, R. Gossein, G. LaColla, P. Sommadossi, J.-P. | 28069 | 6/27/03 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-117055 | 11874-055-117 | 1018 PH | Philippines | Storer, R. Gossein, G. LaColla, P. Sommadossi, J.-P. | 1-2005- 500173 | 6/27/03 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-131055 | 11874-055-131 | 1018 TH | Thailand | Storer, R. Gossein, G. LaColla, P. Sommadossi, J.-P. | 083424 | 6/27/03 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-146055 | 11874-055-146 | 1018 CN | China | Storer, R. Gossein, G. LaColla, P. Sommadossi, J.-P. | 03820501.7 | 6/27/03 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |

LA1-2953113v1
3/4/2009

| <u>Jones Day CAM</u> | <u>Docket No.</u> | <u>Identix Ref. No.</u> | <u>Type Related/ Country</u> | <u>Inventor</u> | <u>Serial No.</u> | <u>Filed</u> | <u>Title</u> |
|--------------------------|-------------------|-----------------------------|--------------------------------------|--|-----------------------|--------------|---|
| 417451-147055 | 11874-055-147 | 1018 ZA | South Africa | LaColla, P. Storer, R. Gossein, G. Sommaossi, J.-P. | 2004/10249 | 6/27/03 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-150055 | 11874-055-150 | 1018 PL | Poland | LaColla, P. Storer, R. Gossein, G. Sommaossi, J.-P. | P-374831 | 6/27/03 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-154055 | 11874-055-154 | 1018 YU | Yugoslavia (former) | Storer, R. LaColla, P. Sommaossi, J.-P. | P-1140004 | 6/27/03 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-158055 | 11874-055-158 | 1018 IL | Israel | Storer, R. Gossein, G. LaColla, P. Sommaossi, J.-P. | 165893 | 6/27/03 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-178055 | 11874-055-178 | 1018 PK | Pakistan | LaColla, P. Storer, R. Gossein, G. Sommaossi, J.-P. | 580/72003 | 6/27/03 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-185055 | 11874-055-185 | 1018 TW | Taiwan | Storer, R. Gossein, G. LaColla, P. Sommaossi, J.-P. | 92/17546 | 6/27/03 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-187055 | 11874-055-187 | 1018 KR | South Korea | LaColla, P. Storer, R. Gossein, G. Sommaossi, J.-P. | 102004-7021286 | 6/27/03 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-189055 | 11874-055-189 | 1018 VN | Vietnam | LaColla, P. Storer, R. Gossein, G. Sommaossi, J.-P. | 1-2005-00107 | 6/27/03 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |
| 417451-214055 | 11874-055-214 | 1018 OA | OAPI | Storer, R. Gossein, G. LaColla, P. Sommaossi, J.-P. | 1200400344 | 6/27/03 | Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections |

1A1-2953113v1
3/4/2009

| <u>Jones Day CAM</u> | <u>Docket No.</u> | <u>Idenix Ref. No.</u> | <u>Type Related Country</u> | <u>Inventor</u> | <u>Serial No.</u> | <u>Filed</u> | <u>Title</u> |
|-------------------------------|-------------------|----------------------------|-------------------------------------|--|--------------------------|--------------------|--|
| 417451-227055 | 11874-055-227 | 1018 EP | EPO | La Colla, P. Storer, R. Goselin, G. Sommadossi, J.-P. | 03761744-6 03761744-6 | 6/27/03 6/27/03 | Modified 2' and 3' Nucleoside Products for Treating Flaviviridae Infections |
| 417451-228055 | 11874-055-228 | 1018 WO | PCT | La Colla, P. Storer, R. Goselin, G. Sommadossi, J.-P. | PCT/IB2003 /003246 | 6/27/03 | Modified 2' and 3' Nucleoside Products for Treating Flaviviridae Infections |
| 417451-241055 | 11874-055-241 | 1018 MY | Malaysia | Storer, R. Goselin, G. La Colla, P. Sommadossi, J.-P. | PI20032435 | 6/27/03 | Modified 2' and 3' Nucleoside Products for Treating Flaviviridae Infections |
| 417451-262055 | 11874-055-262 | 1018 AP | ARIPO | La Colla, P. Storer, R. Goselin, G. Sommadossi, J.-P. | AP/PI2005/0 03212 | 6/27/03 | Modified 2' and 3' Nucleoside Products for Treating Flaviviridae Infections |
| 417451-146144 | 11874-144-146 | 1018 CN (D1V) | China | La Colla, P. Storer, R. Goselin, G. Sommadossi, J.-P. | 2007101933 01.0 | 12/3/07 | Modified 2' and 3' Nucleoside Products for Treating Flaviviridae Infections |
| IDX 1031 Patent Family | | | | | | | |
| 417451-99026 | 11874-026-999 | 1031 US | 11874-016-388 11874-130-388 | Sommadossi, J.-P. La Colla, P. Goselin, G. | 10/607,909 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-99086 | 11874-086-999 | 1031 US CON 1 | CON of 11874-026-999 | Sommadossi, J.-P. Goselin, G. La Colla, P. | 11/516,928 | 9/6/06 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-001026 | 11874-026-001 | 1031 CA | Canada | Sommadossi, J.-P. La Colla, P. Goselin, G. | 2,489,532 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-007026 | 11874-026-007 | 1031 AU | Australia | Sommadossi, J.-P. La Colla, P. Goselin, G. | 2003248748 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-008026 | 11874-026-008 | 1031 NZ | New Zealand | Sommadossi, J.-P. La Colla, P. Goselin, G. | 537662 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |

| <u>Jones Day CAM</u> | <u>Docket No.</u> | <u>Idenix Ref. No.</u> | <u>Type Related/ Country</u> | <u>Inventor</u> | <u>Serial No.</u> | <u>Filed</u> | <u>Title</u> |
|--------------------------|-------------------|----------------------------|--------------------------------------|---|-----------------------|--------------|---|
| 417451-009026 | 11874-026-009 | 1031 MX | Mexico | Sommadossi, J.-P. La Colla, P. Goscelin, G. | PA/2/2004/0 12802 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-013026 | 11874-026-010 | 1031 CL | Chile | Sommadossi, J.-P. La Colla, P. Goscelin, G. | 1338-2003 | 6/30/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-011026 | 11874-026-011 | 1031 PE | Peru | Sommadossi, J.-P. La Colla, P. Goscelin, G. | 000661- 2003 | 6/30/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-012026 | 11874-026-012 | 1031 JP | Japan | Sommadossi, J.-P. La Colla, P. Goscelin, G. | 2004- 518941 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-015026 | 11874-026-015 | 1031 NO | Norway | Sommadossi, J.-P. La Colla, P. Goscelin, G. | 20050490 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-019026 | 11874-026-019 | 1031 RU | Russian Fed. | Sommadossi, J.-P. La Colla, P. Goscelin, G. | 2005102080 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-023026 | 11874-026-023 | 1031 HK | Hong Kong | Sommadossi, J.-P. La Colla, P. Goscelin, G. | 051061143 | 7/1/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-025026 | 11874-026-025 | 1031 VE | Venezuela | Sommadossi, J.-P. La Colla, P. Goscelin, G. | 1099-2003 | 6/30/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-036026 | 11874-026-036 | 1031 AR | Argentina | Sommadossi, J.-P. La Colla, P. Goscelin, G. | P030102363 | 6/30/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-037026 | 11874-026-037 | 1031 BR | Brazil | Sommadossi, J.-P. La Colla, P. Goscelin, G. | P0312278-6 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-039026 | 11874-026-039 | 1031 PY | Paraguay | Sommadossi, J.-P. La Colla, P. Goscelin, G. | 15062/2003 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-040026 | 11874-026-040 | 1031UY | Uruguay | Sommadossi, J.-P. La Colla, P. Goscelin, G. | 27.874 | 6/30/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |

| <u>Jones Day CAM</u> | <u>Docket No.</u> | <u>Idenix Ref. No.</u> | <u>Type Related/ Country</u> | <u>Inventor</u> | <u>Serial No.</u> | <u>Filed</u> | <u>Title</u> |
|--------------------------|-------------------|----------------------------|--------------------------------------|--|-----------------------|--------------|---|
| 417451-041026 | 11874-026-041 | 1031 BO | Bolivia | Sommadossi, J.-P. La Colla, P. Gossein, G. | SP-230149 | 6/30/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-055026 | 11874-026-055 | 1031 SG | Singapore | Sommadossi, J.-P. La Colla, P. Gossein, G. | 200407793-9 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-056026 | 11874-026-056 | 1031 IN | India | Sommadossi, J.-P. La Colla, P. Gossein, G. | 3447DELNP 2005 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-076026 | 11874-026-076 | 1031 ID | Indonesia | Sommadossi, J.-P. La Colla, P. Gossein, G. | WO200500 214 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-078026 | 11874-026-078 | 1031 EG | Egypt | Sommadossi, J.-P. La Colla, P. Gossein, G. | 6162003 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-106026 | 11874-026-106 | 1031 MA | Morocco | Sommadossi, J.-P. La Colla, P. Gossein, G. | 28070 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-117026 | 11874-026-117 | 1031 PH | Philippines | Sommadossi, J.-P. La Colla, P. Gossein, G. | 1-2005- 500172 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-131026 | 11874-026-131 | 1031 TH | Thailand | Sommadossi, J.-P. La Colla, P. Gossein, G. | 083422 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-146026 | 11874-026-146 | 1031 CN | China | Sommadossi, J.-P. La Colla, P. Gossein, G. | 03820701X | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-147026 | 11874-026-147 | 1031 ZA | South Africa | Sommadossi, J.-P. La Colla, P. Gossein, G. | 200410290 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-150026 | 11874-026-150 | 1031 PL | Poland | Sommadossi, J.-P. La Colla, P. Gossein, G. | P-374781 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-154026 | 11874-026-154 | 1031 YU | Yugoslavia (former) | Sommadossi, J.-P. La Colla, P. Gossein, G. | P-113904 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |

LAI-2933113v1
3/4/2009

| <u>Jones Day CAM</u> | <u>Docket No.</u> | <u>Identix Ref. No.</u> | <u>Type Related/ Country</u> | <u>Inventor</u> | <u>Serial No.</u> | <u>Filed</u> | <u>Title</u> |
|--------------------------|-------------------|-----------------------------|--------------------------------------|--|-----------------------|--------------|---|
| 417451-138026 | 11874-026-158 | 1031 IL | Israel | Sommadossi, J.-P. La Colla, P. Gossein, G. | 165757 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-178026 | 11874-026-178 | 1031 PK | Pakistan | Sommadossi, J.-P. La Colla, P. Gossein, G. | 579/2003 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-185026 | 11874-026-185 | 1031 TW | Taiwan | Sommadossi, J.-P. La Colla, P. Gossein, G. | 92117544 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-187026 | 11874-026-187 | 1031 KR | South Korea | Sommadossi, J.-P. La Colla, P. Gossein, G. | 10-2004-7021073 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-189026 | 11874-026-189 | 1031 VN | Vietnam | Sommadossi, J.-P. La Colla, P. Gossein, G. | 1-2005-00106 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-214026 | 11874-026-214 | 1031 OA | OAPI | Sommadossi, J.-P. La Colla, P. Gossein, G. | 1200400343 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-227026 | 11874-026-227 | 1031 EP | EPO | Sommadossi, J.-P. La Colla, P. Gossein, G. | 03762183.6 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-228026 | 11874-026-228 | 1031 WO | PCT | Sommadossi, J.-P. La Colla, P. Gossein, G. | PCT/US2003/020431 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-241026 | 11874-026-241 | 1031 MY | Malaysia | Sommadossi, J.-P. La Colla, P. Gossein, G. | PE20032434 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-262026 | 11874-026-262 | 1031 AP | ARIPO | Sommadossi, J.-P. La Colla, P. Gossein, G. | AP/R/2005/03213 | 6/27/03 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-008086 | 11874-086-008 | (1031) NZ (DIV) | New Zealand | Sommadossi, J.-P. La Colla, P. Gossein, G. | 556268 | 7/2/07 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-055086 | 11874-086-055 | 1031 SG (DIV) | Singapore | Sommadossi, J.-P. La Colla, P. Gossein, G. | 200700648-9 | 1/26/07 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |

LAI-2953113v1
3/4/2009

| <u>Jones Day CAM</u> | <u>Docket No.</u> | <u>Identis Ref. No.</u> | <u>Type Related/ Country</u> | <u>Inventor</u> | <u>Serial No.</u> | <u>Filed</u> | <u>Title</u> |
|-------------------------------|-------------------|-----------------------------|--------------------------------------|---|-----------------------|--------------|---|
| 417451-056086 | 11874-086-056 | 1031 IN (DIV) | India | Somnadosi, J.-P. La Colla, P. Goselin, G. | 8806/DELN P/2007 | 11/15/07 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-140086 | 11874-086-146 | 1031 CN (DIV) | China | Somnadosi, J.-P. La Colla, P. Goselin, G. | 2006/710199 501.7 | 12/10/07 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-147086 | 11874-086-147 | 1031 ZA (DIV) | South Africa | Somnadosi, J.-P. La Colla, P. Goselin, G. | 2006/072118 | 8/29/06 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| 417451-178086 | 11874-086-178 | 1031 PK (DIV) | Pakistan | Somnadosi, J.-P. La Colla, P. Goselin, G. | 547/2007 | 1/20/07 | 2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections |
| IDX 1040 Patent Family | | | | | | | |
| 417451-888077 | 11874-077-888 | 1040 US PROV | | Goselin, G. Seila, F. La Colla, P. Storer, R. Dukhan, D. Leroy, F. | 60/582,182 | 6/23/04 | 5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae |
| 417451-999077 | 11874-077-999 | 1040 US | 11874-077-988 | Goselin, G. Seila, F. La Colla, P. Storer, R. Dukhan, D. Leroy, F. | 11/166,498 | 6/23/05 | 5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae |
| 417451-001077 | 11874-077-001 | 1040 CA | Canada | Goselin, G. Seila, F. La Colla, P. Storer, R. Dukhan, D. Leroy, F. | 2,571,675 | 6/23/05 | 5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae |
| 417451-007077 | 11874-077-007 | 1040 AU | Australia | Goselin, G. Seila, F. La Colla, P. Storer, R. Dukhan, D. Leroy, F. | 2005/256963 | 6/23/05 | 5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae |

1A1-2953113v1
3/4/2009

| <u>Jones Day CAM</u> | <u>Docket No.</u> | <u>Idenix Ref. No.</u> | <u>Type Related/ Country</u> | <u>Inventor</u> | <u>Serial No.</u> | <u>Filed</u> | <u>Title</u> |
|--------------------------|-------------------|----------------------------|--------------------------------------|--|-----------------------|--------------|---|
| 417451-008077 | 11874-077-008 | 1040 NZ | New Zealand | Gossein, G. Seila, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F. | 552612 | 6/23/05 | 5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae |
| 417451-009077 | 11874-077-009 | 1040 MX | Mexico | Gossein, G. Seila, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F. | PA/02006/0 15065 | 6/23/05 | 5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae |
| 417451-012077 | 11874-077-012 | 1040 JP | Japan | Gossein, G. Seila, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F. | 2007- 517330 | 6/23/05 | 5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae |
| 417451-015077 | 11874-077-015 | 1040 NO | Norway | Gossein, G. Seila, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F. | 20070340 | 6/23/05 | 5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae |
| 417451-019077 | 11874-077-019 | 1040 RU | Russian Fed. | Gossein, G. Seila, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F. | 2007102281 | 6/23/05 | 5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae |
| 417451-037077 | 11874-077-037 | 1040 BR | Brazil | Gossein, G. Seila, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F. | PI0512360-7 | 6/23/05 | 5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae |
| 417451-055077 | 11874-077-055 | 1040 SG | Singapore | Gossein, G. Seila, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F. | 200608949- 4 | 6/23/05 | 5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae |

| <u>Jones Day CAM</u> | <u>Docket No.</u> | <u>Identix Ref. No.</u> | <u>Type Related Country</u> | <u>Inventor</u> | <u>Serial No.</u> | <u>Filed</u> | <u>Title</u> |
|--------------------------|-------------------|-----------------------------|-------------------------------------|--|-----------------------|--------------|---|
| 417451-056077 | 11874-077-056 | 1040 IN | India | Gossein, G. Seila, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F. | 470/DEINP 2007 | 6/23/05 | 5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae |
| 417451-078077 | 11874-077-078 | 1040 EG | Egypt | Gossein, G. Seila, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F. | PCT/1254/20 06 | 6/23/05 | 5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae |
| 417451-146077 | 11874-077-146 | 1040 CN | China | Gossein, G. Seila, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F. | 2005800257 94,6 | 6/23/05 | 5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae |
| 417451-154077 | 11874-077-154 | 1040 YU | Yugoslavia (former) | Gossein, G. Seila, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F. | P-2006/04384 | 6/23/05 | 5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae |
| 417451-158077 | 11874-077-158 | 1040 IL | Israel | Gossein, G. Seila, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F. | 180200 | 6/23/05 | 5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae |
| 417451-187077 | 11874-077-187 | 1040 KR | South Korea | Gossein, G. Seila, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F. | 10-2007- 7001047 | 6/23/05 | 5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae |
| 417451-227077 | 11874-077-227 | 1040 EP | EPO | Gossein, G. Seila, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F. | 05778001.7 | 6/23/05 | 5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae |

| <u>Jones Day CAM</u> | <u>Docket No.</u> | <u>Idenix Ref. No.</u> | <u>Type Related/ Country</u> | <u>Inventor</u> | <u>Serial No.</u> | <u>Filed</u> | <u>Title</u> |
|--------------------------|-------------------|----------------------------|--------------------------------------|--|-----------------------|--------------|---|
| 417451-228077 | 11874-077-228 | 1040 WO | PCT | Gossein, G. Seela, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F. | PCT/IB2005 /002768 | 6/23/05 | 5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae |
| 417451-255077 | 11874-077-255 | 1040 UA | Ukraine | Gossein, G. Seela, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F. | 200700649 | 6/23/05 | 5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae |

1A1-2953113v1
3/4/2009